Speaking on myeloproliferative neoplasms and molecular genetics of myeloid neoplasia Prof. Vannucchi has been the Principal Investigator in over 50 clinical trials, primarily focusing on patients with myeloproliferative neoplasms (MPNs). More recently, Prof. Vannucchi has been researching the effects of the COVID-19 pandemic on patients with MPNs and other hematological malignancies, as well testing the safety and efficacy of multiple new treatments, such as ruxolitinib and fedratinib, for the treatment of MPN and myelofibrosis. Prof. Vannucchi is also the coordinator of the MYNERVA-GIMEA trial, which studies early intensification in FLT3-mutated acute myeloid leukemia (AML).